A large American study has quietly redrawn the map of diabetes care, revealing that not all kidneys face the same threat — nor benefit from the same shield. Researchers tracking more than 75,000 patients found that GLP-1 receptor agonists and SGLT-2 inhibitors meaningfully slow kidney decline, but only in those whose urine already carries excess protein, a marker known as albuminuria. The finding is less a discovery of a new drug's power than a reminder of an older medical truth: the right medicine depends on knowing which patient you are treating.